Go Pro
NASDAQ:OSRH

OSR Q2 2025 Earnings Report

OSR logo
$0.25 -0.03 (-9.75%)
Closing price 04:00 PM Eastern
Extended Trading
$0.22 -0.03 (-11.60%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OSR Revenue Results

Actual Revenue
$1.14 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OSR Announcement Details

Quarter
Q2 2025
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

OSR Earnings Headlines

I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had written off. The stock climbed more than 1,100% over the next 3-4 years, with some subscribers reporting gains of $141,000, $272,000, or more. He believes a similar setup is forming now around what he calls the 'Energy Cube' - a compact nuclear system roughly the size of a shipping container, capable of powering up to 1,000 homes with no emissions, 24 hours a day. Bill Gates, Jeff Bezos, Google, and Microsoft have all backed companies in this space. The Nuclear Regulatory Commission is expected to issue a key approval as early as August - the first of its kind for this technology class in over a decade.tc pixel
OSR Holdings Stock Price History
See More OSR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OSR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OSR and other key companies, straight to your email.

About OSR

OSR (NASDAQ:OSRH) Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

View OSR Profile